Modus Therapeutics Holding

Modus Therapeutics Holding is a Swedish biotechnology group focused on developing sevuparin, a patented low-anticoagulant heparinoid drug candidate. The company operates through its wholly owned subsidiary Modus Therapeutics AB and is centered on clinical development for severe diseases with high unmet medical need.

— Modus Therapeutics Holding
%
Sevuparin development100% Clinical and preclinical development of the sevuparin drug candidate across target indications.
Collaborative research programs0% Externally partnered studies and scientific collaborations supporting indication expansion.

Modus does not sell a commercialized drug to end customers; its value creation is directed toward future partners,...

  • Pharmaceutical partnering companiesprimary

    Potential partners that may license, co-develop, or commercialize sevuparin after clinical value is established.

  • Clinical research sitesprimary

    Hospitals and investigators that enroll patients and generate trial data for CKD-anemia and other programs.

  • Academic and scientific collaboratorssecondary

    Universities and research groups that support mechanism, indication, and translational studies.

  • Non-dilutive funding partnerssecondary

    Organizations that may fund selected programs such as severe malaria research.

Modus is headquartered in Stockholm, Sweden, and its operating structure is centered in Sweden through the parent...

  • •Head office in Stockholm, Sweden
  • •Operations conducted through Swedish parent and subsidiary
  • •Clinical study sites in Verona and Pavia, Italy
  • •European partnering activity through BioEurope events
  • •International research collaboration for severe malaria

Modus is focused on building clinical evidence for sevuparin in CKD with anemia, then using that data to support...

01
Advance CKD-anemia clinical developmentshort-term

This is the core value driver for sevuparin and the main basis for future partnering.

02
Create partnering optionalitymedium-term

The company aims to realize value through collaborations with players that have commercial reach.

03
Pursue selective additional indicationsmedium-term

Broader indication work can increase the asset's value while limiting capital intensity through external support.

The business is exposed to clinical development risk because sevuparin remains dependent on trial outcomes, patient...

critical

Drug development failure

Sevuparin's value depends on clinical efficacy, safety, and regulatory acceptance.

Scope
CKD-anemia and other severe indications
Materiality
high
high

Financing risk

The company is research-intensive and relies on external capital to fund operations.

Scope
Ongoing clinical programs and corporate overhead
Materiality
high
high

Trial execution risk

Recruitment, site performance, and data generation affect timelines and study quality.

Scope
Phase IIa CKD study and collaboration programs
Materiality
high
medium

Capital market and macro risk

Interest rates, inflation, and geopolitical uncertainty can weaken financing conditions.

Scope
Equity issuance and investor appetite
Materiality
medium
Development expense capitalization
Higher current-period expenses and no intangible asset build-up
Related-party revenue
Revenue is internal to the group structure and not external sales
Equity and warrant accounting
Dilution, cash proceeds, and potential future equity issuance
Going-concern and financing assumptions
Material uncertainty disclosure and valuation sensitivity

Modular Medical, Inc.

MODD · Surgical & Medical Instruments & Apparatus

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

ESTABLISHMENT LABS HOLDINGS INC.

ESTA · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Definium Therapeutics, Inc.

DFTX · Medicinal Chemicals & Botanical Products

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

: 11/08/2026